VF
INZY

Virtu Financial’s Inozyme Pharma INZY Stock Holding History

Virtu Financial’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,309
Closed -$64K – 1778
2024
Q3 		$64K Buy
+12,309
New +$63.9K ﹤0.01% 971
2024
Q1 		– Sell
-26,678
Closed -$114K – 1723
2023
Q4 		$114K Buy
26,678
+16,160
+154% +$57.4K 0.01% 995
2023
Q3 		$44K Buy
+10,518
New +$53.5K ﹤0.01% 922
2023
Q2 		– Sell
-46,995
Closed -$269K – 1753
2023
Q1 		$269K Buy
+46,995
New +$124K 0.03% 598
2022
Q3 		– Sell
-11,179
Closed -$53K – 1948
2022
Q2 		$53K Buy
+11,179
New +$48.6K ﹤0.01% 1110

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu Financial's INZY Position: Q4 2024 in Review

Virtu Financial sold out of Inozyme Pharma (INZY) in Q4 2024, closing a stake of 12,309 shares — an estimated $64K sold.

Virtu Financial first reported a position in INZY in Q2 2022 and held it in 5 quarters. The position peaked at $269K in Q1 2023. 105 funds tracked by Wall St. Rank hold INZY as of Q4 2024.

  • Virtu Financial reported no remaining Inozyme Pharma position as of Q4 2024 after selling out during the quarter.
  • Virtu Financial sold 12,309 Inozyme Pharma shares in Q4 2024, an estimated $64K.
  • Virtu Financial first reported a position in Inozyme Pharma in Q2 2022 and held it in 5 quarters.
  • Virtu Financial's Inozyme Pharma position peaked at $269K in Q1 2023.
  • 105 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2024.

Based on Virtu Financial's 13F filing for Q4 2024, filed 11 Feb 2025.